New Haven, CTNCT07774455Now EnrollingIRB Ready

Myelofibrosis (MF) Clinical Trial in New Haven, CT

Access cutting-edge myelofibrosis (mf) treatment through this clinical trial at a research site in New Haven. Study-provided care at no cost to qualified participants.

Sponsored by Swedish Orphan Biovitrum

Quick Self-Assessment

See if you qualify for this New Haven location

Preparing your pre-screening questions…

Expert Care in New Haven

Access myelofibrosis (mf) specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related myelofibrosis (mf) treatment provided free

Apply for This New Haven Location

Check if you qualify for this myelofibrosis (mf) clinical trial in New Haven, CT

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to New Haven

    Convenient for CT residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit New Haven site if eligible
  4. 4Begin participation

About This Myelofibrosis (MF) Study in New Haven

This study aims to evaluate real-world treatment patterns and effectiveness of pacritinib, including hematologic and clinical outcomes, and survival through a site-based retrospective chart review of medical records of patients with MF.

Sponsor: Swedish Orphan Biovitrum

Who Can Participate

Inclusion Criteria

Adult patients must be ≥18 years of age at the index date
Patients diagnosed with MF with platelet counts ≥50 x 109/L at the time of treatment initiation with pacritinib. If multiple values are available within 30 days prior to initiating treatment with pacritinib will use the value closest to index date
Patients will be required to have ≥1 month of treatment with pacritinib and ≥6 months of observation from the start of pacritinib unless the patient died within 6 months of starting pacritinib
If peripheral blasts were evaluated prior to index, they must be \<10%. If not evaluated, patients will be included unless a healthcare provider has indicated in the medical record that there is a concern that the patient has transitioned to accelerated/blast phase disease at or prior to index
According to local regulations, waivers of consent will be sought for study patients from the appropriate regulatory authorities and/or the independent ethics committee (IEC)/institutional review board (IRB). For patients not covered by waivers of consent, signed and dated informed consent provided by the patient, or the patient's legally authorized representative(s) for patients under the legal age (with patient assent, as applicable), should be obtained before any study-related activities are undertaken.

Exclusion Criteria

Diagnosis of acute myeloid leukemia prior to index
Physician-concern that the patient has transitioned to accelerated/blast phase disease if peripheral blasts were not evaluated
Treated with 2 or more JAK inhibitors prior to initiating treatment with pacritinib
Treated with pacritinib in a clinical trial setting

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in New Haven?

Yes, this clinical trial (NCT07774455) has an active research site in New Haven, CT that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Myelofibrosis (MF) Treatment Options in New Haven, CT

If you're searching for myelofibrosis (mf) treatment options in New Haven, CT, this clinical trial (NCT07774455) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our New Haven research site is actively enrolling participants for this clinical trial. You'll receive care from experienced myelofibrosis (mf) specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all myelofibrosis (mf) clinical trials near you to find additional studies recruiting in your area.

More Myeloproliferative Neoplasms Trials in New Haven, CT

See all myeloproliferative neoplasms clinical trials recruiting in New Haven — not just this study.

Browse Myeloproliferative Neoplasms Trials in New Haven →

Browse More Trials by Condition

Myeloproliferative Neoplasms TrialsFibromyalgia TrialsMyelofibrosis TrialsAll Conditions →

Ready to Join in New Haven?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · New Haven, CT